Evaluation of response to 13-valent conjugated pneumococcal vaccination in patients with rheumatoid arthritis receiving upadacitinib: results from a phase 2 open-label extension study

OBJECTIVE: To assess the immunogenicity of pneumococcal 13-valent conjugate vaccination (PCV-13) in patients with rheumatoid arthritis receiving upadacitinib and background methotrexate (MTX). METHODS: Eligible patients from the phase 2 open-label extension trial BALANCE-EXTEND (NCT02049138) receivi...

Descripción completa

Detalles Bibliográficos
Autores principales: Winthrop, Kevin, Vargas, Juan Ignacio, Drescher, Edit, Garcia, Conrado, Friedman, Alan, Hendrickson, Barbara, Li, Yihan, Klaff, Justin, Kivitz, Alan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Treatments
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8900062/
https://www.ncbi.nlm.nih.gov/pubmed/35246470
http://dx.doi.org/10.1136/rmdopen-2021-002110

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8900062/
https://www.ncbi.nlm.nih.gov/pubmed/35246470
http://dx.doi.org/10.1136/rmdopen-2021-002110

Ejemplares similares